The pharmaceutical machinery and equipment industry is an indispensable support force in the pharmaceutical field. In recent years, the pharmaceutical machine industry has developed very rapidly, but the competition is also becoming more and more intense.
In the various branches of the pharmaceutical industry, multinational mergers and acquisitions continue to emerge, which can prevent other pharmaceutical companies from challenging their leading position, and they also grasp the resources of the Chinese medicine machine market.
In the fierce competition environment, the pharmaceutical machine industry must first increase the intensity of enterprise innovation. Enterprises should vigorously promote the integration of drug machine equipment innovation and the introduction of digestion and absorption of the ability to re-innovation and promote product development with independent intellectual property rights. Increase investment in independent innovation, focus on breakthroughs in common key technologies, and regard strengthening the capacity for independent innovation as a strategic basis for the development of science and technology as a central link in adjusting the industrial structure and transforming the mode of growth.
In addition, domestic pharmaceutical companies can also use schools and enterprises to jointly learn advanced technologies: in the technical direction, they should strengthen research in automation, manufacturing processes, and materials and materials design, learn advanced foreign technologies, and enable companies to directly interact with these universities. Research institutes unite in various forms, making the company become the main body of technological innovation, making China's pharmaceutical machinery and equipment industry bigger and stronger, and striving to occupy an important position in the international arena.
Multinational companies have absolute advantages in product innovation, quality reliability, and after-sales service. The gradual deployment of their industries will lead to deeper competition in the industry, market sales will be further concentrated in large pharmaceutical equipment companies, and the stronger the stronger The weaker the weaker trend.
In the face of these competitions among foreign pharmaceutical companies, localization of domestic equipment cannot rely solely on policy support. Domestic pharmaceutical companies need to rely more on their own strength to compete with multinational companies.
In the various branches of the pharmaceutical industry, multinational mergers and acquisitions continue to emerge, which can prevent other pharmaceutical companies from challenging their leading position, and they also grasp the resources of the Chinese medicine machine market.
In the fierce competition environment, the pharmaceutical machine industry must first increase the intensity of enterprise innovation. Enterprises should vigorously promote the integration of drug machine equipment innovation and the introduction of digestion and absorption of the ability to re-innovation and promote product development with independent intellectual property rights. Increase investment in independent innovation, focus on breakthroughs in common key technologies, and regard strengthening the capacity for independent innovation as a strategic basis for the development of science and technology as a central link in adjusting the industrial structure and transforming the mode of growth.
In addition, domestic pharmaceutical companies can also use schools and enterprises to jointly learn advanced technologies: in the technical direction, they should strengthen research in automation, manufacturing processes, and materials and materials design, learn advanced foreign technologies, and enable companies to directly interact with these universities. Research institutes unite in various forms, making the company become the main body of technological innovation, making China's pharmaceutical machinery and equipment industry bigger and stronger, and striving to occupy an important position in the international arena.
Multinational companies have absolute advantages in product innovation, quality reliability, and after-sales service. The gradual deployment of their industries will lead to deeper competition in the industry, market sales will be further concentrated in large pharmaceutical equipment companies, and the stronger the stronger The weaker the weaker trend.
In the face of these competitions among foreign pharmaceutical companies, localization of domestic equipment cannot rely solely on policy support. Domestic pharmaceutical companies need to rely more on their own strength to compete with multinational companies.